Our Studies
STEM CELL RESEARCH (SCR)
COMMUNITY BASED RESEARCH INVESTIGATORS
AN EXPERIENCED TEAM OF CLINICAL RESEARCH PROFESSIONALS.
BIOSOLUTIONS
OUR CLINICAL RESEARCH STUDIES
BioSolutions Open Protocol Summaries
INDICATION
AGE CRITERIA
DESCRIPTION
OA knee
≥ 18 years
A 48-Week, Phase 2b/3a, Double-Blind, Randomized, Placebo Controlled, Multi-center, Superiority Study to Evaluate the Efficacy and Safety of Joint Stem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells in patients diagnosed with Knee Osteoarthritis
OA knee
≥ 40 yrs. old
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy and Effectiveness of TG-C in Subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee
OA knee
≥ 18 years
A randomized, two-arm, placebo-controlled, participant and investigator-blinded study investigating the efficacy, safety and tolerability of DFV890 in patients with symptomatic knee osteoarthritis.
Severe Osteoarthritis Pain of the Knee.
≥ 18 years
A phase 3, 16-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint 0.07 mg Dose in the Target Knee Joint of Subjects with Moderate to Severe Osteoarthritis Pain of the Knee.
Diabetic Foot Osteomyelitis due to S. aureus
≥ 18 years
Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Repeat Dose, Multi-Site Study Investigating the Safety, Tolerability, and Efficacy of Personalized Phage Treatment and Standard of Care Antimicrobials for Patients with Diabetic Foot Osteomyelitis due to S. aureus
OAK
40-75 years
Pharmacodynamics of a Single Intra-articular Injection of GNSC-001 Gene Therapy in Subjects with Osteoarthritis of the Knee (DONATELLO)
Rotator Cuff Tendinopathy
≥ 18 years
A randomized, parallel-group, 24-week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult participants with active rotator cuff tendinopathy
BioSolutions Start Up (Upcoming) Protocol Summaries
INDICATION
AGE CRITERIA
DESCRIPTION